Psilocybin-facilitated Smoking Cessation

Since 2008 researchers at the Behavioral Pharmacology Research Unit at Johns Hopkins University School of Medicine have been conducting innovative research examining the potential of the naturally occurring hallucinogen psilocybin as a treatment for nicotine addiction. Led by Principal Investigator Matthew W. Johnson, Ph.D., and Co-Investigator Roland R. Griffiths, Ph.D., an initial pilot study found that combining cognitive behavioral therapy and controlled administration of psilocybin in the laboratory was a safe and feasible approach for helping people who were seeking to quit smoking, and for whom other treatments had failed.

In 2019, the Center for Psychedelic & Consciousness Research (CPCR) was founded at Hopkins to continue investigating how psychedelics affect behavior, mood, cognition, brain function, and biological markers of health. More information can be found on other research being conducted at the CPCR website.

Dr. Matthew Johnson in the session room.

Dr. Matthew Johnson in the session room.